Antifungal prophylaxis in oncohematologic patients: Literature review and recommendations;Profilaxis antifúngica en pacientes oncohematológicos: revisión de la bibliografía médica y recomendaciones

Medicina Clinica

Volumn 134, Issue 5, 2010, Pages 222-233

  Cámara, Rafael de la ^b   Mensa, José ^a   Carreras, Enric ^b   Cuenca Estrella, Manuel ^a   García Rodríguez, José Ángel ^a   Gobernado, Miguel ^a   Picazo, Juan ^a   Aguado, José María ^a   Sanz, Miguel Ángel ^b  

^a Sociedad Española de Quimioterapia SEQ   (Spain)

^b Asociación Madrileña de Hematologiá y Hemoterapia AMHH   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

ARTICLE; HEMATOLOGIC MALIGNANCY; HUMAN; MEDICAL RECORD REVIEW; MYCOSIS; PROPHYLAXIS;

ANTIFUNGAL AGENTS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYCOSES; PRACTICE GUIDELINES AS TOPIC;

EID: 76549089043     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2009.10.036     Document Type: Article

References (171)

1. Prophylaxis and treatment of fungal infections in oncohematological patients. Rev Esp Quimioter 15 (2002) 387-401
2. Mensa J., De la Cámara R., Carreras E., Cuenca Estrella M., García Rodríguez J.A., Gobernado M., et al. Treatment of fungal infections in patients with hematologic neoplasia. Med Clin (Barc) 132 (2009) 507-521
3. Gross P.A., Barrett T.L., Dellinger E.P., Krause P.J., Martone W.J., McGowan Jr. J.E., et al. Purpose of quality standards for infectious diseases. Infectious Diseases Society of America. Clin Infect Dis 18 (1994) 421
4. Bodey G., Bueltmann B., Duguid W., Gibbs D., Hanak H., Hotchi M., et al. Fungal infections in cancer patients: An international autopsy survey. Eur J Clin Microbiol Infect Dis 11 (1992) 99-109
5. Van Burik J.H., Leisenring W., Myerson D., Hackman R.C., Shulman H.M., Sale G.E., et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore) 77 (1998) 246-254
6. Yamazaki T., Kume H., Murase S., Yamashita E., and Arisawa M. Epidemiology of visceral mycoses: Analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol 37 (1999) 1732-1738
7. Denning D.W. Antifungal and surgical treatment of invasive aspergillosis: Review of 2121 published cases. Rev Infect Dis 12 (1997) 1147-1201
8. Lin S., Schranz J., and Teutsch S. Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis 32 (2001) 358-366
9. Roden M.M., Zaoutis T.E., Buchanan W.L., Knudsen T.A., Sarkisova T.A., Schaufele R.L., et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis 41 (2005) 634-653
10. Young R.C., Bennett J.E., Vogel C.L., Carbone P.P., and DeVita V.T. Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) 49 (1970) 147-173
11. Groll A.H., Shah P.M., Mentzel C., Schneider M., Just-Nuebling G., and Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 33 (1996) 23-32
12. Upton A., Kirby K.A., Carpenter P., Boeckh M., and Marr K.A. Invasive aspergillosis following hematopoietic cell transplantation: Outcomes and prognostic factors associated with mortality. Clin Infect Dis 44 (2007) 531-540
13. Neofytos D., Horn D., Anaissie E., Steinbach W., Olyaei A., Fishman J., et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: Analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance Registry. Clin Infect Dis 48 (2009) 265-273
14. Pfaller M.A., and Diekema D.J. Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 20 (2007) 133-163
15. Maertens J., Theunissen K., Verhoef G., Verschakelen J., Lagrou K., Verbeken E., et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study. Clin Infect Dis 41 (2005) 1242-1250
16. Glasmacher A., and Prentice A.G. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. J Antimicrob Chemother 56 (2005) i23-i32
17. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR Morb Mortal Wkly Rep. 2000;49:1-125.
18. Cornely O.A., Bohme A., Buchheidt D., Einsele H., Heinz W.J., Karthaus M., et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the infectious diseases working party of the German Society for Haematology and Oncology. Haematologica 94 (2009) 113-122
19. National Comprehensive Cancer Network. Prevention and treatment of cancer-related infection. NCCN V.1.2008. NCCN Clinical Practice Guidelines in Oncology [serial on the Internet]. 2008 [consultado 3/12/2009]. Disponible en: http://www.nccn.org/professionals/physician_gls/PDF/infections.pdf.
20. De Pauw B.E., and Donnelly J.P. Prophylaxis and aspergillosis -- Has the principle been proven?. N Engl J Med 356 (2007) 409-411
21. Jantunen E., Nihtinen A., Volin L., Juvonen E., Parkkali T., Ruutu T., et al. Candidaemia in allogeneic stem cell transplant recipients: Low risk without fluconazole prophylaxis. Bone Marrow Transplant 34 (2004) 891-895
22. Perfect J.R., Klotman M.E., Gilbert C.C., Crawford D.D., Rosner G.L., Wright K.A., et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 165 (1992) 891-897
23. Riley D.K., Pavia A.T., Beatty P.G., Petersen F.B., Spruance J.L., Stokes R., et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 97 (1994) 509-514
24. Kelsey S.M., Goldman J.M., McCann S., Newland A.C., Scarffe J.H., Oppenheim B.A., et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: A randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 23 (1999) 163-168
25. Tollemar J., Ringden O., Andersson S., Sundberg B., Ljungman P., and Tyden G. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 12 (1993) 577-582
26. Vehreschild J.J., Bohme A., Buchheidt D., Arenz D., Harnischmacher U., Heussel C.P., et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 55 (2007) 445-449
27. Bodey G.P., Samonis G., and Rolston K. Prophylaxis of candidiasis in cancer patients. Semin Oncol 17 (1990) 24-28
28. Chandrasekar P.H., and Gatny C.M. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Bone Marrow Transplantation Team. Chemotherapy 40 (1994) 136-143
29. Goodman J.L., Winston D.J., Greenfield R.A., Chandrasekar P.H., Fox B., Kaizer H., et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326 (1992) 845-851
30. Rotstein C., Bow E.J., Laverdiere M., Ioannou S., Carr D., and Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 28 (1999) 331-340
31. Schaffner A., and Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 172 (1995) 1035-1041
32. Slavin M.A., Osborne B., Adams R., Levenstein M.J., Schoch H.G., Feldman A.R., et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. J Infect Dis 171 (1995) 1545-1552
33. Winston D.J., Chandrasekar P.H., Lazarus H.M., Goodman J.L., Silber J.L., Horowitz H., et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 118 (1993) 495-503
34. Nucci M., Biasoli I., Akiti T., Silveira F., Solza C., Barreiros G., et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 30 (2000) 300-305
35. Menichetti F., Del Favero A., Martino P., Bucaneve G., Micozzi A., Girmenia C., et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 28 (1999) 250-255
36. Benhamou E., Hartmann O., Nogues C., Maraninchi D., Valteau D., and Lemerle J. Does ketoconazole prevent fungal infection in children treated with high dose chemotherapy and bone marrow transplantation? Results of a randomized placebo-controlled trial. Bone Marrow Transplant 7 (1991) 127-131
37. Brincker H. Prevention of mycosis in granulocytopenic patients with prophylactic ketoconazole treatment. Mykosen 26 (1983) 242-247
38. Hansen R.M., Reinerio N., Sohnle P.G., Abrams R.A., Ritch P.S., Libnoch J.A., et al. Ketoconazole in the prevention of candidiasis in patients with cancer. A prospective, randomized, controlled, double-blind study. Arch Intern Med 147 (1987) 710-712
39. Palmblad J., Lonnqvist B., Carlsson B., Grimfors G., Jarnmark M., Lerner R., et al. Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukaemia in adults: More bacteraemias. J Intern Med 231 (1992) 363-370
40. Kern W., Behre G., Rudolf T., Kerkhoff A., Grote-Metke A., Eimermacher H., et al. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: Results of a prospective randomized phase III study. German AML Cooperative Group. Cancer 83 (1998) 291-301
41. Walsh TL, Bachier C, Shaughnessy C, Freytes CO, Callander N, LeMaistre CF, et al. Efficacy of fluconazole prophylaxis for autologous peripheral blood stem cell transplantation: Results of a prospective, randomized, controlled, multicenter, open label study. The American Society of Hematology, 46th Annual Meeting, San Diego. 2004; abstract 5096.
42. Yamac K., Senol E., and Haznedar R. Prophylactic use of fluconazole in neutropenic cancer patients. Postgrad Med J 71 (1995) 284-286
43. Kaptan K., Ural A.U., Cetin T., Avcu F., Beyan C., and Yalcin A. Itraconazole is not effective for the prophylaxis of fungal infections in patients with neutropenia. J Infect Chemother 9 (2003) 40-45
44. Estey E., Maksymiuk A., Smith T., Fainstein V., Keating M., McCredie K.B., et al. Infection prophylaxis in acute leukemia. Comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole, and a combination of the two. Arch Intern Med 144 (1984) 1562-1568
45. Penack O., Schwartz S., Martus P., Reinwald M., Schmidt-Hieber M., Thiel E., et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: Results from a randomized, single-center trial. Ann Oncol 17 (2006) 1306-1312
46. Akiyama H., Mori S., Tanikawa S., Sakamaki H., and Onozawa Y. Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy-induced neutropenic patients with haematological malignancies. Mycoses 36 (1993) 373-378
47. Brammer K.W. Management of fungal infection in neutropenic patients with fluconazole. Haematol Blood Transfus 33 (1990) 546-550
48. Egger T., Gratwohl A., Tichelli A., Uhr M., Stebler Gysi C., Passweg J., et al. Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. A prospective, randomized, single-center study. Support Care Cancer 3 (1995) 139-146
49. Ellis M.E., Clink H., Ernst P., Halim M.A., Padmos A., Spence D., et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 13 (1994) 3-11
50. Menichetti F., Del Favero A., Martino P., Bucaneve G., Micozzi A., D'Antonio D., et al. Preventing fungal infection in neutropenic patients with acute leukemia: Fluconazole compared with oral amphotericin B. The GIMEMA Infection Program. Ann Intern Med 120 (1994) 913-918
51. Meunier F., Aoun M., Janssens M., Dekoster C., and Paesmans M. Chemoprophylaxis of fungal infections in granulocytopenic patients using fluconazole vs oral amphotericin B. Drug Invest 3 (1991) 258-265
52. Ninane J. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group. Eur J Clin Microbiol Infect Dis 13 (1994) 330-337
53. Philpott-Howard J.N., Wade J.J., Mufti G.J., Brammer K.W., and Ehninger G. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. J Antimicrob Chemother 31 (1993) 973-984
54. Rozenberg-Arska M., Dekker A.W., Branger J., and Verhoef J. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. J Antimicrob Chemother 27 (1991) 369-376
55. Van Delden C., Lew D.P., Chapuis B., Rohner P., and Hirschel B. Antifungal prophylaxis in severely neutropenic patients: How much fluconazole is necessary?. Clin Microbiol Infect 1 (1995) 24-30
56. Young G.A., Bosly A., Gibbs D.L., and Durrant S. A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients with leukaemia. Antifungal Prophylaxis Study Group. Eur J Cancer 35 (1999) 1208-1213
57. Donnelly J.P., Starke I.D., Galton D.A., Catovsky D., Goldman J.M., and Darrell J.H. Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia. J Hosp Infect 5 (1984) 83-91
58. Hann I.M., Prentice H.G., Corringham R., Blacklock H.A., Keaney M., Shannon M., et al. Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Lancet 1 (1982) 826-829
59. Jones P.G., Kauffman C.A., McAuliffe L.S., Liepman M.K., and Bergman A.G. Efficacy of ketoconazole v nystatin in prevention of fungal infections in neutropenic patients. Arch Intern Med 144 (1984) 549-551
60. Shepp D.H., Klosterman A., Siegel M.S., and Meyers J.D. Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. J Infect Dis 152 (1985) 1257-1263
61. Vogler W.R., Malcom L.G., and Winton E.F. A randomized trial comparing ketoconazole and nystatin prophylactic therapy in neutropenic patients. Cancer Invest 5 (1987) 267-273
62. Meunier-Carpentier F., Cruciani M., and Klastersky J. Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients. Eur J Cancer Clin Oncol 19 (1983) 43-48
63. Boogaerts M., Maertens J., van Hoof A., de Bock R., Fillet G., Peetermans M., et al. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimicrob Chemother 48 (2001) 97-103
64. Harousseau J.L., Dekker A.W., Stamatoullas-Bastard A., Fassas A., Linkesch W., Gouveia J., et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: A randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 44 (2000) 1887-1893
65. Lass-Florl C., Gunsilius E., Gastl G., Englisch M., Koch G., Ulmer H., et al. Fungal colonization in neutropenic patients: A randomized study comparing itraconazole solution and amphotericin B solution. Ann Hematol 82 (2003) 565-569
66. Vreugdenhil G., Van Dijke B.J., Donnelly J.P., Novakova I.R., Raemaekers J.M., Hoogkamp-Korstanje M.A., et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma 11 (1993) 353-358
67. Annaloro C., Oriana A., Tagliaferri E., Bertolli V., Della Volpe A., Soligo D., et al. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. Haematologica 80 (1995) 512-517
68. Huijgens P.C., Simoons-Smit A.M., van Loenen A.C., Prooy E., van Tinteren H., Ossenkoppele G.J., et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol 52 (1999) 376-380
69. Glasmacher A., Cornely O., Ullmann A.J., Wedding U., Bodenstein H., Wandt H., et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 57 (2006) 317-325
70. Marr K.A., Crippa F., Leisenring W., Hoyle M., Boeckh M., Balajee S.A., et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103 (2004) 1527-1533
71. Morgenstern G.R., Prentice A.G., Prentice H.G., Ropner J.E., Schey S.A., and Warnock D.W. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 105 (1999) 901-911
72. Oren I., Rowe J.M., Sprecher H., Tamir A., Benyamini N., Akria L., et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant 38 (2006) 127-134
73. Winston D.J., Maziarz R.T., Chandrasekar P.H., Lazarus H.M., Goldman M., Blumer J.L., et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 138 (2003) 705-713
74. Bodey G.P., Anaissie E.J., Elting L.S., Estey E., O'Brien S., and Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 73 (1994) 2099-2106
75. Koh L.P., Kurup A., Goh Y.T., Fook-Chong S.M., and Tan P.H. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol 71 (2002) 260-267
76. Wolff S.N., Fay J., Stevens D., Herzig R.H., Pohlman B., Bolwell B., et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: A study of the North American Marrow Transplant Group. Bone Marrow Transplant 25 (2000) 853-859
77. Cornely O.A., Maertens J., Winston D.J., Perfect J., Ullmann A.J., Walsh T.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356 (2007) 348-359
78. Ullmann A.J., Lipton J.H., Vesole D.H., Chandrasekar P., Langston A., Tarantolo S.R., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356 (2007) 335-347
79. MacMillan M.L., Goodman J.L., DeFor T.E., and Weisdorf D.J. Fluconazole to prevent yeast infections in bone marrow transplantation patients: A randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med 112 (2002) 369-379
80. Mattiuzzi G.N., Alvarado G., Giles F.J., Ostrosky-Zeichner L., Cortes J., O'Brien S., et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 50 (2006) 143-147
81. Mattiuzzi G.N., Estey E., Raad I., Giles F., Cortes J., Shen Y., et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 97 (2003) 450-456
82. Mattiuzzi G., Alvarado G., Kantarjian H., Verstovsek S., Cabanillas M., Faderl S., et al. Intravenous voriconazole (IV-VORI) prevents invasive fungal infections (IFI) in patients (pts) with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 104 (2004) Abstract 885
83. Hiemenz J., Cagnoni P., Simpson D., Devine S., Chao N., Keirns J., et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 49 (2005) 1331-1336
84. Van Burik J.A., Ratanatharathorn V., Stepan D.E., Miller C.B., Lipton J.H., Vesole D.H., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39 (2004) 1407-1416
85. Timmers G.J., Zweegman S., Simoons-Smit A.M., van Loenen A.C., Touw D., and Huijgens P.C. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: Data of a prematurely stopped clinical trial. Bone Marrow Transplant 25 (2000) 879-884
86. Robenshtok E., Gafter-Gvili A., Goldberg E., Weinberger M., Yeshurun M., Leibovici L., et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: Systematic review and meta-analysis. J Clin Oncol 25 (2007) 5471-5489
87. Rijnders B.J., Cornelissen J.J., Slobbe L., Becker M.J., Doorduijn J.K., Hop W.C.J., et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: A randomized, placebo-controlled trial. Clin Infect Dis 46 (2008) 1401-1408
88. Wingard J., Carter S.L., Walsh T., Kurtzberg J., Small T., Gersten I.D., et al. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. Blood 110 (2007) abstract 163
89. Falagas M.E., and Vardakas K.Z. Liposomal amphotericin B as antifungal prophylaxis in bone marrow transplant patients. Am J Hematol 81 (2006) 299-300
90. Jorgensen K.J., Gotzsche P.C., and Johansen H.K. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 1 (2006) CD004707
91. Vardakas K.Z., Michalopoulos A., and Falagas M.E. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: A meta-analysis of randomised-controlled trials. Br J Haematol 131 (2005) 22-28
92. Glasmacher A., Prentice A., Gorschluter M., Engelhart S., Hahn C., Djulbegovic B., et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: Evidence from a meta-analysis of 3,597 patients. J Clin Oncol 21 (2003) 4615-4626
93. Gotzsche P.C., and Johansen H.K. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database Syst Rev 2 (2002) CD000026
94. Bow E.J., Laverdiere M., Lussier N., Rotstein C., Cheang M.S., and Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: A meta analysis of randomized-controlled clinical trials. Cancer 94 (2002) 3230-3246
95. Kanda Y., Yamamoto R., Chizuka A., Hamaki T., Suguro M., Arai C., et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 89 (2000) 1611-1625
96. Gotzsche P.C., and Johansen H.K. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ 314 (1997) 1238-1244
97. Hughes W.T., Armstrong D., Bodey G.P., Bow E.J., Brown A.E., Calandra T., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34 (2002) 730-751
98. Walsh T., Anaissie E., Denning D., Herbrecht R., Kontoyiannis D., Marr K., et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46 (2008) 327-360
99. Pappas P.G., Kauffman C.A., Andes D., Benjamin J., Daniel K., Calandra T.F., et al. Clinical practice guidelines for the management of Candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48 (2009) 503-535
100. Maertens J.A., Frere P., Lass-Florl C., Heinz W., and Cornely O.A. Primary antifungal prophylaxis in leukaemia patients. European Journal of Cancer Supplements 5 (2007) 43-48. http://www.ichs.org/ecilslides.htm [consultado 3/12/2009]. Actualizadas en la segunda conferencia en Octubre 2007: http://www.ichs.org/ecilslides.htm
101. Guidelines for the management of bacterial, fungal and viral infections, updated 2007. 2008 [Jan 2008]. [consultado 3/12/2009]. Disponible en: http://www.ichs.org/ecilslides.htm.
102. Slavin M.A., Heath C.H., Thursky K.A., Morrissey C.O., Szer J., Ling L.M., et al. Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy. Intern Med J 38 (2008) 468-476
103. Tanaka J., Kasai M., Masauzi N., Watanabe M., Matsuura A., Morii K., et al. Successful second allogeneic bone marrow transplantation in a relapsed acute myeloid leukemia patient with fungal liver abscess. Ann Hematol 65 (1992) 193-195
104. Richard C., Romon I., Baro J., Insuza A., Loyola I., Zurbano F., et al. Invasive pulmonary Aspergillosis prior to BMT in acute leukemia patients does not predict a poor outcome. Bone Marrow Transplant 12 (1993) 237-241
105. Dear A. Hepatosplenic candidiasis in patients with acute leukemia: What is the optimum prophylaxis following subsequent chemotherapy. Eur J Haematol 52 (1994) 184-186
106. Katayama K., Koizumi S., Yamagami M., Tamaru Y., Ichihara T., Konishi M., et al. Successful peritransplant therapy in children with active hepatosplenic candidiasis. Int J Hematol 59 (1994) 125-130
107. Bjerke J.W., Meyers J.D., and Bowden R.A. Hepatosplenic candidiasis--a contraindication to marrow transplantation?. Blood 84 (1994) 2811-2814
108. Martino R., Nomdedeu J., Altes A., Sureda A., Brunet S., Martínez C., et al. Successful bone marrow transplantation in patients with previous invasive fungal infections: Report of four cases. Bone Marrow Transplant 13 (1994) 265-269
109. Walsh T.J., Whitcomb P.O., Revankar S.G., and Pizzo P.A. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 76 (1995) 2357-2362
110. Offner F., Cordonnier C., Ljungman P., Prentice H.G., Engelhard D., De Bacquer D., et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 26 (1998) 1098-1103
111. Fukuda T., Boeckh M., Guthrie K.A., Mattson D.K., Owens S., Wald A., et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 10 (2004) 494-503
112. Cordonnier C., Maury S., Pautas C., Bastie J.N., Chehata S., Castaigne S., et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 33 (2004) 943-948
113. Cornely O.A., Bohme A., Reichert D., Reuter S., Maschmeyer G., Maertens J., et al. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J Antimicrob Chemother 61 (2008) 939-946
114. Cordonnier C, Einsele H, Rovira M, Maertens J, Olavarria E, Faucher C, et al. Voriconazole for secondary prophylaxis of invasive fungal infection in allogeneic stem cell transplant recipients: Results of the VOSIFI Study. On Behalf of the VOSIFI Study Group and the Infectious Diseases Working Party of the European Bone and Marrow Transplantation Group. Blood. 2008;112(11):1159.
115. National Comprehensive Cancer Network. Prevention and treatment of cancer-related infection. NCCN V.2.2007. NCCN Clinical Practice Guidelines in Oncology [serial on the Internet]. 2007 [consultado 3/12/2009]. Disponible en: http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf.
116. Kruger W.H., Bohlius J., Cornely O.A., Einsele H., Hebart H., Massenkeil G., et al. Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the infectious diseases working party (AGIHO) of the German Society of Haematology and Oncology. Ann Oncol 16 (2005) 1381-1390
117. Prentice H.G., Kibbler C.C., and Prentice A.G. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 110 (2000) 273-284
118. De la Cámara R. Antifungal prophylaxis in haematology patients. Clin Microbiol Infect 12 (2006) 65-76
119. Bow E.J. Of yeasts and hyphae: A hematologist's approach to antifungal therapy. Hematology 2006 (2006) 361-367
120. McLintock L.A., Jordanides N.E., Allan E.K., Copland M., Stewart K., Parker A., et al. The use of a risk group stratification in the management of invasive fungal infection: A prospective validation. Br J Haematol 124 (2004) 403-404
121. Mahfouz T., and Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs 4 (2003) 974-990
122. Malagola M., Peli A., Damiani D., Candoni A., Tiribelli M., Martinelli G., et al. Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: Retrospective analysis of 224 cases. Eur J Haematol 81 (2008) 354-363
123. García-Vidal C., Upton A., Kirby K.A., and Marr K.A. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: Biological risk factors for infection according to time after transplantation. Clin Infect Dis 47 (2008) 1041-1050
124. Wald A., Leisenring W., van Burik J.A., and Bowden R.A. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 175 (1997) 1459-1466
125. Marr K.A., Carter R.A., Crippa F., Wald A., and Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34 (2002) 909-917
126. Marr K.A., Carter R.A., Boeckh M., Martin P., and Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood 100 (2002) 4358-4366
127. Gratwohl A., Brand R., Frassoni F., Rocha V., Niederwieser D., Reusser P., et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: An EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 36 (2005) 757-769
128. Banoo S., Bell D., Bossuyt P., Herring A., Mabey D., Poole F., et al. Evaluation of diagnostic tests for infectious diseases: General principles. Nat Rev Micro 5 (2007) S21-S31
129. Pfeiffer C.D., Fine J.P., and Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: A meta-analysis. Clin Infect Dis 42 (2006) 1417-1427
130. Ruiz I, Rovira M, Gavalda J, Molina A, Jarque I, de la Cámara R, et al. Proven or probable invasive fungal infections (IFI) in hematopoietic stem cell transplant (HSCT) recipients. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 2006:M-888.
131. Pagano L., Caira M., Nosari A., Van Lint M.T., Candoni A., Offidani M., et al. Fungal infections in recipients of hematopoietic stem cell transplants: Results of the SEIFEM B-2004 Study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 45 (2007) 1161-1170
132. McNeil M.M., Nash S.L., Hajjeh R.A., Phelan M.A., Conn L.A., Plikaytis B.D., et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 33 (2001) 641-647
133. Prentice A.G., Glasmacher A., and Djulbegovic B. In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy. Br J Haematol 132 (2006) 656-658 author reply 8-9
134. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Gersten ID, et al. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. ASH Annual Meeting Abstracts. 2007;110:163.
135. Conneally E., Cafferkey M.T., Daly P.A., Keane C.T., and McCann S.R. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant 5 (1990) 403-406
136. Myers S.E., Devine S.M., Topper R.L., Ondrey M., Chandler C., O'Toole K., et al. A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. Leuk Lymphoma 8 (1992) 229-233
137. Hertenstein B., Kern W.V., Schmeiser T., Stefanic M., Bunjes D., Wiesneth M., et al. Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann Hematol 68 (1994) 21-26
138. Erjavec Z., Woolthuis G.M., de Vries-Hospers H.G., Sluiter W.J., Daenen S.M., De Pauw B., et al. Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur J Clin Microbiol Infect Dis 16 (1997) 364-368
139. Schwartz S., Behre G., Heinemann V., Wandt H., Schilling E., Arning M., et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: Results of a prospective randomized multicenter trial. Blood 93 (1999) 3654-3661
140. Monforte V., Roman A., Gavalda J., Bravo C., Tenorio L., Ferrer A., et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: Study of risk factors. J Heart Lung Transplant 20 (2001) 1274-1281
141. Palmer S.M., Drew R.H., Whitehouse J.D., Tapson V.F., Davis R.D., McConnell R.R., et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 72 (2001) 545-548
142. Drew R.H., Dodds Ashley E., Benjamin Jr. D.K., Duane Davis R., Palmer S.M., and Perfect J.R. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 77 (2004) 232-237
143. Alexander B.D., Dodds Ashley E.S., Addison R.M., Alspaugh J.A., Chao N.J., and Perfect J.R. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 8 (2006) 13-20
144. Goodwin M.L., and Drew R.H. Antifungal serum concentration monitoring: An update. J Antimicrob Chemother 61 (2008) 17-25
145. Andes D., Pascual A., and Marchetti O. Antifungal therapeutic drug monitoring - established and emerging indications. Antimicrob Agents Chemother 53 (2009) 24-34
146. Stevens D.A., Kan V.L., Judson M.A., Morrison V.A., Dummer S., Denning D.W., et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 30 (2000) 696-709
147. Walsh T.J., Raad I., Patterson T.F., Chandrasekar P., Donowitz G.R., Graybill R., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis 44 (2007) 2-12
148. Smith J., Safdar N., Knasinski V., Simmons W., Bhavnani S.M., Ambrose P.G., et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 50 (2006) 1570-1572
149. US Food and Drug Administration. Briefing document for voriconazole. En: US Food and Drug Administration, editor. Washington, DC. [consultado 3/12/2009]. Disponible en: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2.htm
150. Pascual A., Calandra T., Bolay S., Buclin T., Bille J., and Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46 (2008) 201-211
151. Trifilio S., Singhal S., Williams S., Frankfurt O., Gordon L., Evens A., et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 40 (2007) 451-456
152. Wheat L.J., Freifeld A.G., Kleiman M.B., Baddley J.W., McKinsey D.S., Loyd J.E., et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 Update by the Infectious Diseases Society of America. Clin Infect Dis 45 (2007) 807-825
153. Lewis R.E. Editorial commentary: What is the "Therapeutic Range" for voriconazole?. Clin Infect Dis 46 (2008) 212-214
154. Trifilio S., Ortiz R., Pennick G., Verma A., Pi J., Stosor V., et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 35 (2005) 509-513
155. Trifilio S., Pennick G., Pi J., Zook J., Golf M., Kaniecki K., et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 109 (2007) 1532-1535
156. Trifilio S.M., Yarnold P.R., Scheetz M.H., Pi J., Pennick G., and Mehta J. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother 53 (2009) 1793-1796
157. Imhof A., Schaer D.J., Schanz U., and Schwarz U. Neurological adverse events to voriconazole: Evidence for therapeutic drug monitoring. Swiss Med Wkly 136 (2006) 739-742
158. Weiler S., Zoller H., Graziadei I., Vogel W., Bellmann-Weiler R., Joannidis M., et al. Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis. Antimicrob Agents Chemother 51 (2007) 3459-3460
159. Zonios D.I., Gea-Banacloche J., Childs R., and Bennett J.E. Hallucinations during voriconazole therapy. Clin Infect Dis 47 (2008) e7-e10
160. Denning D.W., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34 (2002) 563-571
161. Potoski B.A., and Brown J. The safety of voriconazole. Clin Infect Dis 35 (2002) 1273-1275
162. Trifilio S, Singhal S, Williams S, Winter J, Tallman M, Gordon L, et al. Voriconazole therapeutic drug monitoring: Relationship between drug levels and liver function tests. ASH Annual Meeting Abstracts. 2006;108:2950.
163. Tan K., Brayshaw N., Tomaszewski K., Troke P., and Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 46 (2006) 235-243
164. Lutsar I., Hodges M.R., Tomaszewski K., Troke P.F., and Wood N.D. Safety of voriconazole. Clin Infect Dis 36 (2003) 1087-1088
165. Pasqualotto A.C., Shah M., Wynn R., and Denning D.W. Voriconazole plasma monitoring. Arch Dis Child 93 (2008) 578-581
166. Posaconazole FDA 102 Briefing Document. Clinical Pharmacology and biopharmaceutics review [consultado 04/4/2009]. Disponible en: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022003s000_NoxafilTOC.cfm.
167. Thompson III G.R., Rinaldi M.G., Pennick G., Dorsey S.A., Patterson T.F., and Lewis II J.S. Posaconazole therapeutic drug monitoring: A reference laboratory experience. Antimicrob Agents Chemother 53 (2009) 2223-2224
168. Krishna G., Martinho M., Chandrasekar P., Ullmann A.J., and Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 27 (2007) 1627-1636
169. Dodds Ashley E., Lewis R., Lewis J., Martin C., and Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis 43 (2006) S28-S39
170. Upton A., McCune J.S., Kirby K.A., Leisenring W., McDonald G., Batchelder A., et al. Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant 13 (2007) 760-764
171. Marks DI, Kibbler C, Pagliuca A, Ribaud P, Solano C, Heussel CP, et al. Voriconazole (VOR) vs itraconazole (ITR) for primary prophylaxis of invasive fungal infection (IFI) in allogeneic hematopoietic cell transplant (HCT) recipients. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2009 San Francisco. 2009:M-1249a.